Zai Lab (NASDAQ:ZLAB - Get Free Report) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Zai Lab to post earnings of ($0.65) per share and revenue of $108.53 million for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.
Shares of ZLAB opened at $30.97 on Thursday. The stock has a 50-day moving average of $26.66 and a two-hundred day moving average of $25.07. Zai Lab has a one year low of $13.48 and a one year high of $36.60. The stock has a market cap of $3.39 billion, a P/E ratio of -11.18 and a beta of 1.02.
Separately, Cantor Fitzgerald raised Zai Lab to a "strong-buy" rating in a report on Wednesday, February 5th.
Get Our Latest Report on Zai Lab
In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the transaction, the insider now directly owns 33,834 shares of the company's stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.88% of the stock is currently owned by insiders.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.